v3.25.4
Revenue - Additional Information (Detail)
€ in Thousands
1 Months Ended 12 Months Ended
Nov. 30, 2024
EUR (€)
Jan. 31, 2024
EUR (€)
Nov. 30, 2023
USD ($)
Dec. 31, 2025
EUR (€)
CommercialCustomer
Dec. 31, 2024
EUR (€)
CommercialCustomer
Dec. 31, 2023
EUR (€)
CommercialCustomer
Disclosure of performance obligations [line items]            
Revenue       € 720,132 € 363,641 € 266,718
Number of commercial customers | CommercialCustomer       2 4 4
Novo Nordisk [member]            
Disclosure of performance obligations [line items]            
Upfront development and regulatory milestones potentially to be received € 285,000          
Upfront fee for exclusive license 100,000          
Maximum additional development and regulatory milestones potentially to be received € 77,500          
Third Party Investors [Member]            
Disclosure of performance obligations [line items]            
Commitment from investors   € 150,000        
Teijin [Member]            
Disclosure of performance obligations [line items]            
Upfront payment received | $     $ 70,000,000      
Maximum additional development and regulatory milestones potentially to be received | $     $ 175,000,000      
Licenses [Member] | Novo Nordisk [member]            
Disclosure of performance obligations [line items]            
Upfront payment received         € 95,300  
Licenses [Member] | Third Party Investors [Member]            
Disclosure of performance obligations [line items]            
Upfront payment received         € 27,100  
Licenses [Member] | Teijin [Member]            
Disclosure of performance obligations [line items]            
Upfront payment received           € 63,700
Commercial customers [member] | Bottom of range [member]            
Disclosure of performance obligations [line items]            
Percentage of revenue from commercial products       10.00% 10.00%